Galapagos and MorphoSys’ $111 Million Global License Agreement With Novartis Pharma AG

Goodwin advised Galapagos NV and MorphoSys AG on their global license agreement with Novartis Pharma AG to cover the development and commercialization of their joint program…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now